en/
19 pages · Updated September 7, 2026
Pages
- Press releases | Chiesi Farmaceutici S.p.A.
- Patients | Chiesi Farmaceutici S.p.A.
- Clinical trial transparency and data sharing
- Environment | Chiesi Farmaceutici S.p.A.
- Pipeline | Chiesi Farmaceutici S.p.A.
- Pharmacovigilance | Chiesi Farmaceutici S.p.A.
- Air | Chiesi Farmaceutici S.p.A.
- Sustainability | Chiesi Farmaceutici S.p.A.
- Home | Chiesi Farmaceutici S.p.A.
- Rare | Chiesi Farmaceutici S.p.A.
- Science and innovation | Chiesi Farmaceutici S.p.A.
- Our focus | Chiesi Farmaceutici S.p.A.
- Chiesi and Gossamer Bio Announce Seralutinib
- Medical information | Chiesi Farmaceutici S.p.A.
- SpeakUp&BeHeard | Chiesi Farmaceutici S.p.A.
- chiesi-group-signs-an-option-agreement-with-inhibrx-for-development-and-commercialization-of-inbrx-101-28aat-fc-29.html
- Care | Chiesi Farmaceutici S.p.A.
- Website terms of use | Chiesi Farmaceutici S.p.A.
- Chiesi Group to Acquire KalVista Pharmaceuticals